This research article by Slavenka Kam-Hansen et al. investigates how variations in medication labeling affect placebo and drug effects in episodic migraine treatment. The study involved 66 patients who experienced six migraine attacks, receiving either placebo or Maxalt under different labeling conditions. Results showed that both placebo and Maxalt were more effective when labeled positively, and open-label placebo was more effective than no treatment. The study highlights the importance of information and the ritual of pill-taking in medical care.
documents/EFTA01195776.pdf
{}